慢性鼻窦炎合并免疫缺陷的医学与手术治疗结局:系统综述
该系统综述检索MEDLINE、Embase和CENTRAL至2019年4月,纳入13项研究,评估成人慢性鼻窦炎(CRS)合并原发性或继发性免疫缺陷的医学与手术治疗结局。抗生素单药治疗未显示显著改善临床、影像或内镜结局;免疫球蛋白替代治疗可能减少原发性免疫缺陷(PID)患者急慢性鼻窦炎发作频率,但可能不改善鼻窦症状;内镜鼻窦手术(ESS)与症状、疾病特异性生活质量、内镜评分和影像评分改善相关,平均修正手术率为14%。结论认为CRS合并免疫缺陷患者可能从ESS获益,医学治疗证据有限,免疫球蛋白治疗在PID合并CRS患者中可能有潜在作用。
要点
- 抗生素单药治疗未显著改善CRS合并免疫缺陷患者的临床、影像或内镜结局。
- 免疫球蛋白替代治疗可能减少PID患者急慢性鼻窦炎发作频率,但可能不改善鼻窦症状。
- ESS与症状、生活质量、内镜和影像评分改善相关,平均修正手术率14%。
核心结论
- 基于现有证据,CRS合并免疫缺陷患者可能从ESS获益。
- 支持该人群医学治疗的数据总体有限,但免疫球蛋白治疗在PID合并CRS患者中可能有潜在作用。
研究设计与样本
- 系统综述检索MEDLINE、Embase和Cochrane CENTRAL从建库至2019年4月,筛选2459篇文章,最终纳入13项研究。
- 纳入研究包括2项前瞻性双盲安慰剂对照试验、2项前瞻性病例对照研究、2项前瞻性队列研究和7项病例系列。
- 研究对象为成人CRS合并基础原发性或继发性免疫缺陷患者,报告可测量的医学或手术治疗结局。
- 研究异质性高,无法进行meta分析。
主要发现
- 抗生素单药治疗与临床、影像或内镜结局的显著改善无关。
- 免疫球蛋白替代治疗可能减少PID患者急慢性鼻窦炎发作频率,但可能不改善鼻窦症状。
- 8项研究报告了ESS结局,发现手术与症状、疾病特异性生活质量、内镜评分和影像评分改善相关。
- 报告的ESS平均修正手术率为14%。
临床怎么用
- 对于CRS合并免疫缺陷患者,ESS可作为改善症状、生活质量和内镜/影像评分的治疗选择。
- 抗生素单药治疗不应期望显著改善临床、影像或内镜结局。
- PID合并CRS患者可考虑免疫球蛋白替代治疗以减少鼻窦炎发作频率,但需注意其可能不改善鼻窦症状。
局限性
- 纳入研究异质性高,无法进行meta分析。
- 支持医学治疗的数据总体有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Immunodeficiency is a risk factor for recalcitrant chronic rhinosinusitis (CRS). Currently, there is no consensus on effective treatment modalities for immunodeficient CRS patients. This review aims to evaluate the existing evidence on the treatment outcomes and its limitations in patients with CRS and immunodeficiency. METHODS: MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials (CENTRAL) were searched from inception to April 2019 for studies reporting measurable medical or surgical treatment outcomes for adult patients with CRS and underlying primary or secondary immunodeficiency. RESULTS: Of the 2459 articles screened, 13 studies met the inclusion criteria: 2 prospective double-blind placebo-controlled trials, 2 prospective case-control studies, 2 prospective cohort studies, and 7 case series. The high degree of study heterogeneity precluded a meta-analysis. Antibiotic monotherapy was not linked with significant improvement in clinical, radiographic, or endoscopic outcomes. Immunoglobulin replacement therapy may potentially reduce the frequency of acute or chronic sinusitis in patients with primary immunodeficiency (PID) but may not improve their sinonasal symptoms. Outcomes from endoscopic sinus surgery (ESS) were reported in 8 studies, which found that surgery was linked with improvement in symptoms, disease-specific quality of life, endoscopy scores, and radiographic scores. The average reported ESS revision rate was 14%. CONCLUSION: Patients with CRS and immunodeficiency likely benefit from ESS based on the available evidence. Data supporting medical therapy in this targeted population is limited overall, but there may be a potential role for immunoglobulin therapy in patients with PID and CRS.
引用
- Samargandy S, Grose E, Chan Y, et al. Medical and surgical treatment outcomes in patients with chronic rhinosinusitis and immunodeficiency: a systematic review. Int Forum Allergy Rhinol. 2020. PMID: 32668102. doi:10.1002/alr.22647
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。